Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
DURHAM, N.C. and BEIJING, June 8, 2024 -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK),...
DURHAM, N.C. and BEIJING, June 8, 2024 -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK),...
